DNTH Stock: Price, Earnings History and SEC Filings
Dianthus Therapeutics, Inc. (DNTH) last traded at $82.38, down 0.39% on the latest session and down 6.4% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-0.90 against an analyst estimate of $-0.93, a beat of 3.2%.
$82.38 -0.39%
1 month-6.44%
52-week high$117.88
52-week low$32.28
Volume496,893
ExchangeNasdaqCM
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
DNTH earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 4, 2026 | $-0.90 | $-0.93 | +3.23% |
| Mar 2026 | May 5, 2026 | $-0.85 | $-1.17 | +27.35% |
| Dec 2025 | Mar 9, 2026 | $-1.43 | $-0.98 | -45.92% |
| Sep 2025 | Nov 5, 2025 | $-0.97 | $-0.86 | -12.79% |
DNTH beat the analyst EPS estimate in 2 of its last 4 reported quarters. Source: Nasdaq.
Latest SEC filings for DNTH
SEC filing data is not available right now. You can search for DNTH on SEC EDGAR.
DNTH news
- Regeneron (REGN) Q3 Earnings and Revenues Beat EstimatesOct 30, 2026 · finance.yahoo.com
- Halozyme Therapeutics (HALO) Reports Next Week: Wall Street Expects Earnings GrowthOct 29, 2026 · finance.yahoo.com
- Dianthus Therapeutics (DNTH) Stock May Be Above Fair Value Following Its 5x RunOct 20, 2026 · finance.yahoo.com
About Dianthus Therapeutics, Inc.
Dianthus Therapeutics, Inc. (DNTH) is a US-listed public company on Nasdaq.